Literature DB >> 25333402

Expanding the indications of pancreas transplantation alone.

Arianeb Mehrabi1, Mohammad Golriz, Fatemeh Adili-Aghdam, Mohammadreza Hafezi, Maryam Ashrafi, Christian Morath, Martin Zeier, Thilo Hackert, Peter Schemmer.   

Abstract

OBJECTIVES: Total pancreatectomy (TP) is associated with postoperative endocrine and exocrine insufficiency. Especially, insulin therapy reduces quality of life and may lead to long-term complications. We review the literature with regard to the potential option of pancreas transplantation alone (PTA) after TP in patients with chronic pancreatitis or benign tumors.
METHODS: A MEDLINE search (1958-2013) using the terminologies pancreas transplantation, pancreas transplantation alone, total pancreatectomy, morbidity, mortality, insulin therapy, and quality of life was performed. In addition, the current book and congress publications were reviewed.
RESULTS: Total pancreatectomy after benign and borderline tumors as well as chronic pancreatitis is continuously increasing. Despite improvement of exogenous insulin therapy, more than 50% of these patients experience severe glucose control problems, which cause up to 50% long-term mortality. Pancreas transplantation alone can cure both endocrine and exocrine insufficiency and reduce the associated risks. The 3-year graft and patient survival rates after PTA are up to 73% and 100%, respectively.
CONCLUSIONS: Pancreas transplantation alone after TP in patients with pancreatitis or benign tumors improves the recipient's quality of life and reduces long-term mortality. Considering the amount of available organs and potential candidates, PTA can be a treatment option for patients after TP with chronic pancreatitis or benign tumors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25333402     DOI: 10.1097/MPA.0000000000000181

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  5 in total

1.  Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial in Type 1 Diabetes Complicated by Severe Hypoglycemia.

Authors:  Eric D Foster; Nancy D Bridges; Irene D Feurer; Thomas L Eggerman; Lawrence G Hunsicker; Rodolfo Alejandro
Journal:  Diabetes Care       Date:  2018-03-21       Impact factor: 19.112

2.  Chronic Pancreatitis and Diabetes Mellitus.

Authors:  Yu Kuei Lin; Philip C Johnston; Karla Arce; Betul A Hatipoglu
Journal:  Curr Treat Options Gastroenterol       Date:  2015-09

Review 3.  Familial pancreatic cancer: Concept, management and issues.

Authors:  Hiroyuki Matsubayashi; Kyoichi Takaori; Chigusa Morizane; Hiroyuki Maguchi; Masamichi Mizuma; Hideaki Takahashi; Keita Wada; Hiroko Hosoi; Shinichi Yachida; Masami Suzuki; Risa Usui; Toru Furukawa; Junji Furuse; Takamitsu Sato; Makoto Ueno; Yoshimi Kiyozumi; Susumu Hijioka; Nobumasa Mizuno; Takeshi Terashima; Masaki Mizumoto; Yuzo Kodama; Masako Torishima; Takahisa Kawaguchi; Reiko Ashida; Masayuki Kitano; Keiji Hanada; Masayuki Furukawa; Ken Kawabe; Yoshiyuki Majima; Toru Shimosegawa
Journal:  World J Gastroenterol       Date:  2017-02-14       Impact factor: 5.742

Review 4.  Surveillance of Individuals with a Family History of Pancreatic Cancer and Inherited Cancer Syndromes: A Strategy for Detecting Early Pancreatic Cancers.

Authors:  Hiroyuki Matsubayashi; Yoshimi Kiyozumi; Hirotoshi Ishiwatari; Katsuhiko Uesaka; Masataka Kikuyama; Hiroyuki Ono
Journal:  Diagnostics (Basel)       Date:  2019-10-31

5.  Expanding pancreas donor pool by evaluation of unallocated organs after brain death: Study protocol clinical trial (SPIRIT Compliant).

Authors:  Yakup Kulu; Elias Khajeh; Omid Ghamarnejad; Mohammadsadegh Nikdad; Mohammadsadegh Sabagh; Sadeq Ali-Hasan-Al-Saegh; Silvio Nadalin; Markus Quante; Przemyslaw Pisarski; Bernd Jänigen; Christoph Reißfelder; Markus Mieth; Christian Morath; Benjamin Goeppert; Peter Schirmacher; Oliver Strobel; Thilo Hackert; Martin Zeier; Rainer Springel; Christina Schleicher; Markus W Büchler; Arianeb Mehrabi
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.